OncoMatch/Clinical Trials/NCT06520176
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
Is NCT06520176 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for multiple myeloma.
Treatment: Etoposide · Cytarabine · Pegfilgrastim · Cyclophosphamide · G-CSF · G-CSF — This is a prospective, randomized, two-arm, multicenter, exploratory study aimed at evaluating the efficacy and safety of the combination of etoposide, cytarabine and Pegfilgrastim (EAP regimen) for mobilizing hematopoietic stem cells in patients with newly diagnosed multiple myeloma (NDMM). A total of 99 NDMM patients will be enrolled and randomly assigned to receive either the EAP regimen or the GC regimen (cyclophosphamide+ G-CSF) to mobilize hematopoietic stem cells. Subsequently, the mobilization effects and adverse reactions of all patients will be observed and compared.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: hematopoietic stem cell mobilization
Lab requirements
Kidney function
Serum creatinine clearance rate ≤30% [excluded]
Liver function
Serum direct bilirubin (DBIL) >2× ULN; AST or ALT >3× ULN [excluded]
Cardiac function
Cardiac function class II or higher or cardiac ejection fraction <40% [excluded]
Cardiac function class II or higher or cardiac ejection fraction <40%. Serum direct bilirubin (DBIL)>2× ULN. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3× ULN. Serum creatinine clearance rate≤30%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify